Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

HPV vaccination linked to lower risk of pregnancy complications (opens in a new tab)

news-medical.net · 2026-10-07

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Four of five claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 4 supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe associations were stronger among women vaccinated before age 17.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the general point that risk reductions were more pronounced among women vaccinated at younger ages. However, it does not provide the specific age category 'before age 17,' stratified estimates, or interaction-test details, so that exact framing is not verifiable from the supplied abstract-depth evidence.

1

Study evidence

Risk reductions associated with pre-pregnancy quadrivalent HPV vaccination were generally more pronounced among women vaccinated at younger ages.

“Effect modification by age at human papillomavirus vaccination was assessed.”
Claim 2 of 5SupportedA study published in The BMJ found that women vaccinated against HPV were less likely to experience several pregnancy and childbirth complications, particularly preterm birth.View evidenceHide evidence

Why this verdict

The abstract-level profile supports an associational statement that pre-pregnancy quadrivalent HPV vaccination was associated with lower odds of adverse pregnancy outcomes, with preterm birth as the primary focus and significant adjusted associations for preterm birth outcomes. Although this is a headline claim and is not hedged in the claim text, it does not state causation, and the story’s body caveat about the observational design is consistent with the paper profile.

1

Study evidence

Quadrivalent HPV vaccination before pregnancy was associated with lower odds of preterm birth (<37 weeks) after adjustment.adjusted odds ratio 0.95 (95% CI 0.91 to 0.99)

“Nationwide, population based matched case-control study.”
2

Study evidence

Quadrivalent HPV vaccination before pregnancy was associated with lower adjusted odds of preterm prelabour rupture of membranes in the adjusted matched analyses reported in the abstract.adjusted OR 0.93 (95% CI 0.87 to 1.00)

“preterm prelabour rupture of membranes, prelabour rupture of membranes, small for gestational age infant (<10th centile), severe small for gestational age infant (<3rd centile), stillbirth, and neonatal mortality as secondary outcomes.”
Claim 3 of 5SupportedThe study investigated HPV vaccination in relation to preterm birth, premature rupture of membranes, babies being small for their gestational age, stillbirth, and neonatal mortality.View evidenceHide evidence

Why this verdict

The listed outcomes match the paper profile: primary outcomes included preterm birth and spontaneous preterm birth, and secondary outcomes included preterm prelabour rupture of membranes/prelabour rupture of membranes, small for gestational age, stillbirth, and neonatal mortality.

1

Study evidence

Quadrivalent HPV vaccination before pregnancy was associated with lower odds of preterm birth (<37 weeks) after adjustment.adjusted odds ratio 0.95 (95% CI 0.91 to 0.99)

“Nationwide, population based matched case-control study.”
2

Study evidence

Quadrivalent HPV vaccination before pregnancy was associated with lower adjusted odds of preterm prelabour rupture of membranes in the adjusted matched analyses reported in the abstract.adjusted OR 0.93 (95% CI 0.87 to 1.00)

“preterm prelabour rupture of membranes, prelabour rupture of membranes, small for gestational age infant (<10th centile), severe small for gestational age infant (<3rd centile), stillbirth, and neonatal mortality as secondary outcomes.”
Claim 4 of 5SupportedAmong 624,713 pregnancies in first-time mothers aged 16 to 35 in Swedish registers from 2006 to 2023, 92,620 had received the quadrivalent HPV vaccine before pregnancy.View evidenceHide evidence

As statedaround 5% less likely to give birth prematurely and around 15% less likely to give birth very prematurely

Why this verdict

The abstract-level profile reports 624,713 singleton births among nulliparous women aged 16–35 in Sweden from 2006 to 2023, with 92,620 vaccinated before pregnancy. The stated magnitudes correspond to adjusted odds ratios of 0.95 for preterm birth and 0.85 for very preterm birth, though the paper reports odds ratios rather than direct risk reductions.

1

Study evidence

Quadrivalent HPV vaccination before pregnancy was associated with lower odds of preterm birth (<37 weeks) after adjustment.adjusted odds ratio 0.95 (95% CI 0.91 to 0.99)

“Nationwide, population based matched case-control study.”
Claim 5 of 5SupportedBecause the study was observational, the researchers said it was not possible to conclude that the lower risk was caused by HPV vaccination.View evidenceHide evidence

Why this verdict

The paper profile identifies the study as observational, specifically a nationwide matched case-control study using registry data. Framing the findings as unable to establish causation is consistent with that design and with the profile’s caveats about residual confounding.

1

Study evidence

Quadrivalent HPV vaccination before pregnancy was associated with lower odds of preterm birth (<37 weeks) after adjustment.adjusted odds ratio 0.95 (95% CI 0.91 to 0.99)

“Nationwide, population based matched case-control study.”
2

Study evidence

Risk reductions associated with pre-pregnancy quadrivalent HPV vaccination were generally more pronounced among women vaccinated at younger ages.

“Effect modification by age at human papillomavirus vaccination was assessed.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • For several secondary endpoints, the abstract does not provide outcome-specific estimates or confidence intervals, limiting assessment of magnitude and precision at abstract depth.

    The story mentions the outcomes investigated but does not convey the abstract-depth limitation that estimates are not available for some secondary endpoints such as SGA <10th centile, stillbirth, neonatal mortality, and non-preterm PROM.

    From nationwide matched case-control

  • Multiplicity and secondary-endpoint interpretation: multiple secondary outcomes were analyzed, and the abstract does not report correction for multiple comparisons or a prespecified secondary-outcome plan.

    This interpretation-relevant limitation appears in the profile but is not included in the story’s stated caveats.

    From nationwide matched case-control

6 things the story did carry across
  • Nationwide Swedish observational matched case-control design using registry data, not a randomized trial.
  • Study population and exposure: 624,713 singleton births among nulliparous women aged 16–35 in Sweden during 2006–2023; 92,620 had received quadrivalent HPV vaccination before pregnancy.
  • Primary finding: pre-pregnancy quadrivalent HPV vaccination was associated with modestly lower adjusted odds of preterm birth, including aOR 0.95 for preterm birth and aOR 0.85 for very preterm birth.
  • Secondary outcomes included preterm/prelabour rupture of membranes, small for gestational age including severe SGA, stillbirth, and neonatal mortality.
  • Age-at-vaccination effect modification: the abstract reports stronger risk reductions at younger vaccination ages but does not provide age cutpoints, stratum-specific estimates, or interaction statistics.
  • Residual confounding remains possible despite adjustment because the study is observational.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate the association between quadrivalent HPV vaccination before pregnancy and risk of adverse pregnancy outcomes (primary focus on preterm birth outcomes) in a nationwide Swedish nulliparous singleton-birth population using a matched case-control design.Nationwide matched case-control studyExpand

In plain English

Nationwide, population-based matched case-control study in Sweden (2006–2023) evaluating the association between quadrivalent human papillomavirus (HPV) vaccination before pregnancy and risk of adverse pregnancy outcomes among 624,713 nulliparous singleton births (92,620 vaccinated). Using conditional logistic regression with adjustment for confounders, vaccination before pregnancy was associated with modestly lower odds of several adverse pregnancy outcomes, including preterm birth and severe small for gestational age, with stronger reductions observed for vaccination at younger ages.

Key findings

  • Quadrivalent HPV vaccination before pregnancy was associated with lower odds of preterm birth (<37 weeks) after adjustment.adjusted odds ratio 0.95 (95% CI 0.91 to 0.99)
  • Vaccination before pregnancy was associated with lower odds of very preterm birth (28–31 weeks).adjusted odds ratio 0.85 (95% CI 0.75 to 0.97)
“Nationwide, population based matched case-control study.”
2secondary dataAssess whether the association between pre-pregnancy quadrivalent HPV vaccination and adverse pregnancy outcomes differs by age at vaccination (effect modification).Effect-modification assessment (interaction/stratified analysis) within matched case-controlExpand

In plain English

The study explicitly assessed effect modification by age at quadrivalent HPV vaccination within a nationwide matched case-control analysis of pregnancy outcomes and reported that risk reductions associated with pre-pregnancy vaccination were generally more pronounced among women vaccinated at younger ages. The abstract does not provide stratified effect estimates, age categories, or statistical details of the interaction tests.

Key findings

  • Risk reductions associated with pre-pregnancy quadrivalent HPV vaccination were generally more pronounced among women vaccinated at younger ages.
“Effect modification by age at human papillomavirus vaccination was assessed.”
What this piece can’t prove
  • The abstract lacks details on how age-at-vaccination effect modification was operationalized (age cutpoints, continuous vs categorical), and does not report stratum-specific estimates or interaction p-values.

1 further detail could not be confirmed from the summary.

3secondary dataEstimate associations between pre-pregnancy quadrivalent HPV vaccination and additional adverse pregnancy outcomes beyond primary preterm-birth endpoints (e.g., SGA, stillbirth, neonatal mortality).nationwide matched case-controlExpand

In plain English

In a nationwide matched case-control study of 624,713 singleton births in Sweden (2006–2023), the authors assessed associations between quadrivalent HPV vaccination before pregnancy and multiple secondary adverse pregnancy outcomes (preterm prelabour rupture of membranes, prelabour rupture of membranes, small for gestational age [<10th centile], severe small for gestational age [<3rd centile], stillbirth, and neonatal mortality) using conditional logistic regression with adjustment for confounders. The abstract reports lower adjusted odds for all included adverse outcomes, with reported statistically significant associations for preterm prelabour rupture of membranes (adjusted OR 0.93, 95% CI 0.87–1.00) and severe small for gestational age infant (adjusted OR 0.92, 95% CI 0.87–0.97); effect estimates for some secondary endpoints (small for gestational age <10th centile, stillbirth, neonatal mortality, and prelabour rupture of membranes [non‑preterm]) are not provided in the abstract. Risk reductions were generally larger among women vaccinated at younger ages.

Key findings

  • Quadrivalent HPV vaccination before pregnancy was associated with lower adjusted odds of preterm prelabour rupture of membranes in the adjusted matched analyses reported in the abstract.adjusted OR 0.93 (95% CI 0.87 to 1.00)
  • Quadrivalent HPV vaccination before pregnancy was associated with lower adjusted odds of severe small for gestational age infant (<3rd centile) in adjusted analyses reported in the abstract.adjusted OR 0.92 (95% CI 0.87 to 0.97)
“preterm prelabour rupture of membranes, prelabour rupture of membranes, small for gestational age infant (<10th centile), severe small for gestational age infant (<3rd centile), stillbirth, and neonatal mortality as secondary outcomes.”
What this piece can’t prove
  • Observational matched case-control design; potential for residual confounding despite adjustment (not detailed in abstract).
  • Multiple secondary endpoints were analyzed; abstract does not report correction for multiple comparisons or a prespecified analysis plan for secondary outcomes.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

Pattern of high-risk HPV viral load after quadrivalent HPV vaccination in patients treated by conization

2016 · Crossref

Source (opens in a new tab)
Candidate

Predicted impact of HPV vaccination and primary HPV screening on precancer treatment rates and adverse pregnancy outcomes in Australia 2010-2070: Modelling in a high income, high vaccination coverage country with HPV-based cervical screening.

Vaccine · 2025 · PubMed

Tessa (opens in a new tab)Source (opens in a new tab)

And 9 more candidates considered.